A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Emma Dean et al.|Annals of Oncology|2016Cited by 145
610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent MesotheliomaJean‐Charles Soria, M.J. Millward, Gérard Zalcman et al.|European Journal of Cancer|2012Cited by 8